436 For the treatment of osteoporosis in postmenopausal women who would otherwise be eligible for funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia), AND have at least two of the following:
- Age greater than 75 years old
- A prior fragility fracture
- A bone mineral density (BMD) T-score less than or equal to -2.5
NOTE: Patients receiving Aclasta should not be receiving concomitant bisphosphonate therapy. The recommended dose of Aclasta (zoledronic acid) is a single IV injection of 5mg, once yearly.
LU Authorization Period: Indefinite.